Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Articles, guides, and regulatory updates from our community.
New research explores how mitochondrial dysfunction drives postoperative cognitive decline and which targeted therapies show neuroprotective promise in preclinical studies.
By Peptide Association Research Team
New research suggests elamipretide (SS-31) may support recovery after spinal cord injury by preserving mitochondrial function and reducing cell death in animal models.
By Peptide Association Research Team
New research suggests the mitochondria-targeted peptide SS-31 may help protect cardiac function during doxorubicin chemotherapy. Learn what the study found.
By Peptide Association Research Team
Recent 2026 study shows SS-31 peptide in targeted liposomes may improve mitochondrial function in fat cells. Animal research suggests potential for obesity treatment.
By Peptide Association Research Team
New research explores how the mitochondria-targeted antioxidant peptide SS-31 may help protect cardiac function in laboratory studies of doxorubicin toxicity.
By Peptide Association Research Team
Research reveals how mitochondria-targeted liposomes enhance thermogenesis in fat cells, offering potential obesity treatment through improved cellular metabolism.
By Peptide Association Research Team
How mitochondrial-derived peptides like MOTS-c and humanin intersect with NAD+ biology to influence aging, metabolic health, and cellular resilience.
By Peptide Association Editorial Team